目的 探討地奧心血康軟膠囊聯(lián)合酒石酸美托洛爾片治療冠心病心絞痛的臨床療效。方法 納入2023年3月—12月新鄉(xiāng)醫(yī)學(xué)院第一附屬醫(yī)院140例冠心病心絞痛患者，按照隨機(jī)數(shù)字表法將所有研究對(duì)象分為對(duì)照組和治療組，各組70例。對(duì)照組口服酒石酸美托洛爾片，25 mg/次，2次/d。治療組在對(duì)照組的基礎(chǔ)上口服地奧心血康軟膠囊，1粒/次，3次/d。兩組均治療4周。比較兩組的臨床療效、心絞痛癥狀、心功能指標(biāo)、血清血管內(nèi)皮細(xì)胞功能因子和炎癥因子指標(biāo)。結(jié)果 治療后，對(duì)照組的總有效率為81.43%；治療組的總有效率為94.29%，組間比較差異顯著（P＜0.05）。治療后，兩組心絞痛發(fā)作頻率、VAS評(píng)分均顯著降低（P＜0.05），且治療組的心絞痛發(fā)作頻率、VAS評(píng)分低于對(duì)照組（P＜0.05）。治療后，兩組每搏輸出量（SV）、心臟指數(shù)（CI）、心輸出量（CO）和左室射血分?jǐn)?shù)（LVEF）均顯著升高（P＜0.05），且治療組的SV、CI、CO和LVEF高于對(duì)照組（P＜0.05）。治療后，兩組血清內(nèi)皮素1（ET-1）、血管緊張素II（Ang-II）水平均顯著降低，而血清一氧化氮（NO）水平顯著升高（P＜0.05），且治療組的血清ET-1、Ang-II水平低于對(duì)照組，而血清NO水平顯著高于對(duì)照組（P＜0.05）。治療后，兩組血清白細(xì)胞介素-6（IL-6）、腫瘤壞死因子（TNF-α）和超敏C反應(yīng)蛋白（hs-CRP）水平均顯著降低（P＜0.05），且治療組血清IL-6、TNF-α和hs-CRP水平顯著低于對(duì)照組（P＜0.05）。結(jié)論 地奧心血康軟膠囊聯(lián)合酒石酸美托洛爾片治療冠心病心絞痛的臨床療效顯著，能顯著改善冠心病心絞痛患者的臨床癥狀，可能與改善血管內(nèi)皮細(xì)胞功能、降低機(jī)體炎癥因子水平有關(guān)。

Objective To investigate the clinical efficacy of Di'ao Xinxuekang Soft Capsule combined with Metoprolol Tartrate Tablets in treatment of angina pectoris of coronary heart disease. Methods A total of 140 patients with angina pectoris of coronary heart disease from March to December, 2023 in First Affiliated Hospital of Xinxiang Medical University were enrolled and divided into control group and treatment group according to random number tablet method, and each group had 70 cases. Patients in the control group were po administered with Metoprolol Tartrate Tablets, 25 mg/time, twice daily. Patients in the treatment group were po administered Di'ao Xinxuekang Soft Capsules on the basis of the control group, 1 capsule/time, three times daily. Both groups were treated for 4 weeks. The clinical efficacy, angina symptoms, cardiac function indicators, serum vascular endothelial cell function factors, and inflammatory factors were compared between the two groups. Results After treatment, the total effective rate of the control and treatment group were 81.43% and 94.29%, respectively, with statistical significance between two groups (P < 0.05). After treatment, the frequency of angina pectoris and VAS scores in both groups were significantly decreased (P < 0.05), and the frequency of angina pectoris and VAS scores in the treatment group were lower than those in the control group (P < 0.05). After treatment, SV, CI, CO, and LVEF in both groups were significantly increased (P < 0.05), and SV, CI, CO, and LVEF in the treatment group were higher than those in the control group (P < 0.05). After treatment, the levels of serum ET-1 and Ang-II in both groups were significantly decreased, while the level of serum NO was significantly increased (P < 0.05). The levels of serum ET-1 and Ang-II in the treatment group were lower than those in the control group, while the level of serum NO was significantly higher than that in the control group (P < 0.05). After treatment, the levels of IL-6, TNF-α, and hs-CRP in both groups were significantly decreased (P < 0.05), and the levels of IL-6, TNF-α, and hs-CRP in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Di'ao Xinxuekang Soft Capsule combined with Metoprolol Tartrate Tablets can significantly improve the clinical symptoms and cardiac function in patients with angina pectoris of coronary heart disease, which may be related to improving the function of vascular endothelial cells and decreasing the expression of inflammatory factors.

R972

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（LHGJ20220588）